The goal of our study is to assess whether restoring p53 function via the tumor-targeting nanomedicine SGT-53 would convert otherwise unresponsive lung cancers into tumors that are less refractory to anti-PD-1 immunotherapy. Here, PDCD1 is linked to lung cancer.